Fusion Proteins Or Polypeptides Patents (Class 435/69.7)
-
Publication number: 20140343249Abstract: A cell-killing peptide, more specifically a cell-killing CKP fusion peptide (CTD7:CKP) is disclosed, wherein a cell-killing peptide (CKP) comprising 10 amino acids in MTD of Noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing CKP fusion peptide induces strong cell necrosis at various cancer cell lines (HeLa, HCT116, MCF-7, A549, BJAB, CT26, PC3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells. Therefore, it can be broadly used to human body for treating various diseases requiring cell death, particularly, as an anti-cancer drug.Type: ApplicationFiled: December 15, 2011Publication date: November 20, 2014Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITYInventors: Tae-Hyoung Kim, Ae Ran Moon, Ji Young Kim
-
Patent number: 8889377Abstract: Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a family C G-protein coupled receptor (GPCR), wherein the first portion comprises the TM1, TM2 and TM3, regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, wherein the second portion comprises the TM4, TM5 TM6 and TM7 regions of the GPCR.Type: GrantFiled: May 16, 2013Date of Patent: November 18, 2014Assignee: ConfometRx, Inc.Inventor: Brian Kobilka
-
Patent number: 8889376Abstract: A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.Type: GrantFiled: August 6, 2010Date of Patent: November 18, 2014Assignee: Samsung Electronics Co., Ltd.Inventors: Jae-Il Lee, Young-Sun Lee, Tae-Soo Lee
-
Patent number: 8889949Abstract: The present invention relates to a method for increasing resistance of monocot plants against abiotic stress which comprises a step of transforming monocot plants with a recombinant plasmid containing a fused gene (TPSP) of trehalose-6-phosphate synthetase (TPS) gene and trehalose-6-phosphate phosphatase (TPP) gene to express the TPSP gene while maintaining normal growth and development characteristics. The present invention can increase the resistance of monocot plants against various stresses so that it can greatly contribute to the improvement of production and quality of valuable agricultural crops. The present invention also relates to a transgenic monocot plant, plant cell, or protoplast transformed with a nucleic acid encoding an enzyme for trehalose biosynthesis, under control of an inducible promoter, that increases tolerance to low temperature, salt, and water stress.Type: GrantFiled: January 3, 2007Date of Patent: November 18, 2014Assignees: Cornell Research Foundation, Inc., Myongji University Industry and Academia Cooperation FoundationInventors: Ray J. Wu, Ajay K. Garg, Ju-Kon Kim, Baek-Hie Nahm, Yang-Do Choi, In-Cheol Jang, Won-Bin Choi, Yeon-Seak Kim, Chung-Ho Kim, Sang-Ik Song
-
Publication number: 20140335085Abstract: A new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production. A fusion protein, characterized in that, a protein (X) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type is connected to a protein (A) containing a fragment of the antibody heavy chain constant region which exhibits the antibody-dependent cellular cytotoxicity with a linker peptide (L) consisting of one or more amino acid(s), wherein the protein (X), the linker peptide (L) and the protein (A) are connected in this order by means of peptide bond from N terminal to C terminal.Type: ApplicationFiled: April 2, 2012Publication date: November 13, 2014Applicant: Nihon Pharmaceutical Co., Ltd.Inventors: Masayuki Homma, Takahisa Kogure, Kenji Nakajima
-
Patent number: 8883450Abstract: A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I): (X1)iX2X3X4SX5X6X7, wherein: X1 is a peptide containing from 3 to 6 amino acids, i equal to 0 or 1, X2 is a peptide containing from 3 to 9 hydrophobic amino acids, X3 is a peptide containing from 3 to 5 amino acids, the peptide including at least 3 contiguous or non-contiguous leucines X4 is a peptide containing from 2 to 5 amino acids chosen from Ala, Thr, Ser, Gln, Ile, Met, X5 is Ala or Val, X6 is Gln, Asn or His, X7 is Ala or Cys, provided that when the signal peptide originates from a natural precursor of a specific protein, the polypeptide of interest is different from the protein.Type: GrantFiled: March 17, 2011Date of Patent: November 11, 2014Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventor: Alexandre Fontayne
-
Patent number: 8883161Abstract: The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.Type: GrantFiled: February 26, 2010Date of Patent: November 11, 2014Assignee: Protein Design Lab, Ltd.Inventor: Xiaoqing Qiu
-
Publication number: 20140329718Abstract: The invention relates to a genetically encoded fluorescent sensor for nicotinamide adenine dinucleotide, as well as methods of preparation and uses thereof. In one aspect, this invention relates to a sensor for detecting nicotinamide adenine dinucleotide, particularly, a recombinant fluorescent fusion protein sensor for detecting nicotinamide adenine dinucleotide. In one specific aspect, this invention relates to a recombinant fluorescent fusion protein sensor for detecting reduced nicotinamide adenine dinucleotide (NADH); in another specific aspect, this invention relates to a recombinant fluorescent fusion protein sensor for detecting oxidized nicotinamide adenine dinucleotide (NAD+); in yet another aspect, the invention relates to a recombinant fluorescent fusion protein sensor for detecting the ratio of reduced to oxidized nicotinamide adenine dinucleotide.Type: ApplicationFiled: September 26, 2012Publication date: November 6, 2014Applicant: East China University of Science and TechnologyInventors: Yi Yang, Jing Jin, Yuzheng Zhao, Qingxun Hu
-
Patent number: 8877895Abstract: A pro-polypeptide which is useful for the expression of a polypeptide of interest in a prokaryotic cell. Therefore the pro-polypeptide is fused to the N-terminus of the polypeptide of interest. The pro-polypeptide as reported herein provides for improved expression yields and improves the handling of the fusion polypeptide (downstream processing, purification). For example, efficient endotoxin removal is effected while the protein of interest comprising the pro-polypeptide is bound e.g. to an affinity chromatography material. Thereafter the pro-polypeptide can efficiently be cleaved from the polypeptide of interest by the incorporated protease cleavage site with the cognate protease.Type: GrantFiled: August 25, 2011Date of Patent: November 4, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Patent number: 8878002Abstract: The present invention relates to DYAD genes, mutants thereof, and use of them for making plants that retain heterozygosity of the female parent plant. The invention also encompasses plants, plant tissues, and seeds of plants that have a dyad phenotype and so retain heterozygosity of the female parent, either constitutively or conditionally. The invention is useful for propagating desired hybrid phenotypes in a manner of an apomictic plant and for increasing the ploidy of a plant genotype, which may result in plants having increased biomass.Type: GrantFiled: November 13, 2006Date of Patent: November 4, 2014Assignee: Council of Scientific and Industrial ResearchInventors: Imran Siddiqi, Maruthachalam Ravi, Mohan Prem Anand Marimuthu
-
Publication number: 20140322257Abstract: The present invention refers to recombinant DNA molecules codifying fused peptides from different allergens from Blomia tropicalis and Dermatophagoides pteronyssinus having potential usefulness in prevention and treatment of allergies caused by domestic mites. Specifically, the invention discloses fusion proteins composed by different fragments of allergens Der p 1, Der p 2, Der p 7, Der p 8, Blo t 5, Blo t 8, Blo t 18, Blo t 12 and Blo t 13 with reduced serum IgE reactivity in allergic and non allergic individuals. It also discloses methods for production of these molecules in an expression system based on E. coli and purification. The invention refers also to effective and safe vaccines.Type: ApplicationFiled: September 20, 2012Publication date: October 30, 2014Applicant: UNIVERSIDAD DE CARTAGENAInventors: Leonardo Puerta Llerna, Luis Caraballo, José Fernando Cantillo
-
Publication number: 20140322205Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).Type: ApplicationFiled: May 5, 2014Publication date: October 30, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: J. Timothy STOUT, Trevor J. MCFARLAND, Binoy APPUKUTTAN
-
Patent number: 8871486Abstract: The present invention relates to methods for producing a secreted polypeptide having biological activity, comprising: (a) transforming a fungal host cell with a fusion protein construct encoding a fusion protein, which comprises: (i) a first polynucleotide encoding a signal peptide; (ii) a second polynucleotide encoding at least a catalytic domain of an endoglucanase or a portion thereof; and (iii) a third polynucleotide encoding at least a catalytic domain of a polypeptide having biological activity; wherein the signal peptide and at least the catalytic domain of the endoglucanase increases secretion of the polypeptide having biological activity compared to the absence of at least the catalytic domain of the endoglucanase; (b) cultivating the transformed fungal host cell under conditions suitable for production of the fusion protein; and (c) recovering the fusion protein, a component thereof, or a combination thereof, having biological activity, from the cultivation medium.Type: GrantFiled: May 16, 2014Date of Patent: October 28, 2014Assignee: Novozymes, Inc.Inventor: Sandra Merino
-
Patent number: 8871468Abstract: A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.Type: GrantFiled: May 31, 2011Date of Patent: October 28, 2014Assignee: Ohio UniversityInventor: Marcia J. Kieliszewski
-
Publication number: 20140315253Abstract: Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventors: Jianwu Dai, Bing Chen, Hang Lin, Wenjie Sun, Wenxue Zhao
-
Publication number: 20140315804Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: GENZYME CORPORATIONInventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
-
Publication number: 20140316109Abstract: Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair.Type: ApplicationFiled: June 30, 2014Publication date: October 23, 2014Inventors: Jianwu Dai, Bing Chen, Hang Lin, Wenjie Sun, Wenxue Zhao
-
Patent number: 8865652Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.Type: GrantFiled: December 22, 2010Date of Patent: October 21, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Martin Oft, Catherine Sheppard, John Mumm, Lingling Wu
-
Patent number: 8865430Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: GrantFiled: May 13, 2013Date of Patent: October 21, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
-
Patent number: 8865428Abstract: Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by Bacillus thuringiensis, and (b) introducing the DNA into a host bacterium to transform the same, and (c) allowing the fusion protein to be expressed in the transformed host bacterium, as well as a method for production of the protein (A) itself comprising a further step of removing the peptide chain (B) from the fusion protein obtained.Type: GrantFiled: July 30, 2009Date of Patent: October 21, 2014Assignees: National University Corporation Okayama University, Japan Lamb Co., Ltd.Inventors: Hiroshi Sakai, Toru Hayakawa
-
Patent number: 8859232Abstract: The present invention relates to fusion proteins comprising protein light switches and methods of photomanipulating the activity of the proteins. The invention further relates to polynucleotides and vectors encoding the fusion proteins, cells comprising the fusion proteins, and methods of using the fusion proteins to study protein function and analyze subcellular activity, as well as diagnostic and therapeutic methods.Type: GrantFiled: July 1, 2010Date of Patent: October 14, 2014Assignee: The University of North Carolina at Chapel HillInventors: Klaus Hahn, Yi Wu, Brian Kuhlman
-
Patent number: 8859231Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.Type: GrantFiled: June 2, 2009Date of Patent: October 14, 2014Assignee: Wyeth LLCInventors: Jose M. Galarza, Theresa E. Latham
-
Patent number: 8859507Abstract: A protein complex comprising an in vitro stabilization protein, a membrane translocation sequence domain, a biologically active molecule, and an in vivo stabilization protein, as well as methods for the use and production thereof.Type: GrantFiled: August 16, 2012Date of Patent: October 14, 2014Assignee: Samsung Electronics Co., Ltd.Inventor: Jae-il Lee
-
Publication number: 20140303345Abstract: Certain embodiments provide a GPCR fusion protein. In particular embodiments, the GPCR fusion protein comprises: a) a G-protein coupled receptor (GPCR); and b) an autonomously folding stable domain, where the autonomously folding stable domain is N-terminal to the GPCR and is heterologous to the GPCR. The GPCR fusion protein is characterized in that is crystallizable under lipidic cubic phase crystallization conditions. In certain embodiments, the GPCR fusion protein may be crystallizable in a complex with a G-protein or in a complex with an antibody that binds to the IC3 loop of the GPCR.Type: ApplicationFiled: May 16, 2014Publication date: October 9, 2014Inventors: Brian K. Kobilka, Yaozhong Zou
-
Patent number: 8853159Abstract: The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for preparing a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.Type: GrantFiled: May 29, 2012Date of Patent: October 7, 2014Assignee: Biocompatibles UK LtdInventors: Peter Geigle, Christine Wallrapp, Eric Thoenes
-
Patent number: 8853165Abstract: The present invention relates to a peptide having bone tissue regeneration capacity and binding to a surface of apatite. More particularly, a peptide is provided having bone tissue regeneration capacity and specifically binding to a surface of apatite mineral, capable of being stably immobilized to the surface of apatite mineral to retain effective activity and exhibit bone regeneration effects for a long time, by linking an amino acid sequence having bone tissue regeneration capacity and an amino acid sequence having apatite-binding capacity to each other to thereby provide a peptide having both bone-forming effects and binding capacity to the surface of apatite mineral. A composition for bone tissue regeneration containing the peptide is further provided.Type: GrantFiled: March 9, 2011Date of Patent: October 7, 2014Assignee: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Sang Hoon Rhee, Jue-Yeon Lee
-
Patent number: 8853381Abstract: The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct.Type: GrantFiled: August 16, 2013Date of Patent: October 7, 2014Assignee: Novozymes A/SInventors: Tomoko Matsui, Henriette Draborg, Steffen Danielsen
-
Patent number: 8853367Abstract: The present invention provides methods for identifying agents capable of modulating RANK-mediated signaling pathways. The present invention also provides compositions and methods of using the same to treat osteoporosis or other RANK-related diseases. The present invention is based on the functional and structural analysis of three TRAF-binding motifs (PTM)—namely, PTM3, PTM5, and PTM6, each of which has been found to play a distinct role in the activation of RANK-mediated intracellular signaling. These PTMs can be used to screen for RANK modulators. These PTMs also represent potential drug targets for diseases that are associated with abnormal RANK expression or activity.Type: GrantFiled: September 14, 2005Date of Patent: October 7, 2014Assignee: The UAB Research FoundationInventors: Xu Feng, Wei Liu, Duorong Xu
-
Patent number: 8852602Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: October 18, 2011Date of Patent: October 7, 2014Inventors: David M. Koelle, Lawrence Corey
-
Patent number: 8846860Abstract: A modular peptide design strategy wherein the modular peptide has two functional units separated by a spacer portion is disclosed. More particularly, the design strategy combines a hydroxyapatite-binding portion and a biomolecule-derived portion. The modular peptides have improved non-covalent binding to the surface of the HA-based materials, and are capable of initiating osteogenesis, angiogenesis, and/or osteogenic differentiation.Type: GrantFiled: February 19, 2013Date of Patent: September 30, 2014Assignee: Wisconsin Alumni Research FoundationInventors: William L. Murphy, Jae Sung Lee, Mark D. Markel, Ben K. Graf
-
Patent number: 8846052Abstract: A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.Type: GrantFiled: April 28, 2009Date of Patent: September 30, 2014Assignees: Idemitsu Kosan Co., Ltd., National University Corporation Nara Institute of Science and TechnologyInventors: Kazutoshi Sawada, Takeshi Matsui, Mayumi Yoshida, Nobuo Yoshida, Kyoko Yoshida
-
Publication number: 20140286986Abstract: Isolated polypeptides are provided that comprise a cholera toxin B subunit variant having one or more modifications to increase the expression of the polypeptide in a plant cell. Nucleic acids sequences, vectors, and plant cells for expressing the cholera toxin B subunit variant polypeptides are also provided. Further provided are methods for producing the cholera toxin B subunit variant polypeptides that include the steps of transforming a plant cell with a nucleic acid encoding the cholera toxin B subunit variant polypeptides; expressing the variant polypeptides; and purifying the polypeptides. Still further provided are methods of isolating the variant polypeptides that include the steps of obtaining a plant cell expressing the cholera toxin B subunit variant polypeptides; extracting the cholera toxin B subunit variant polypeptides from the plant cell; and purifying the cholera toxin B subunit variant polypeptides. Methods of eliciting an immune response are also provided.Type: ApplicationFiled: March 14, 2012Publication date: September 25, 2014Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Nobuyuki Matoba, Krystal Hamorsky
-
Publication number: 20140286898Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicant: Amgen Inc.Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
-
Publication number: 20140274812Abstract: The disclosure describes methods that include providing a first nucleic acid having a sequence encoding a first set comprising one or more transcription activator-like effector (TALE) repeat domains and/or one or more portions of one or more TALE repeat domains; contacting the first nucleic acid with a first enzyme, wherein the first enzyme creates a first ligatable end; providing a second nucleic acid having a sequence encoding a second set comprising one or more TALE repeat domains and/or one or more portions of one or more TALE repeat domains; contacting the second nucleic acid with a second enzyme, wherein the second enzyme creates a second ligatable end, and wherein the first and second ligatable ends are compatible; and ligating the first and second nucleic acids through the first and second ligatable ends to produce a first ligated nucleic acid, wherein the first ligated nucleic acid is linked to a solid support, and wherein the first ligated nucleic acid encodes a polypeptide comprising said first andType: ApplicationFiled: July 12, 2012Publication date: September 18, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: J. Keith Joung, Jeffry D. Sander
-
Publication number: 20140274911Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: MOMENTA PHARMACEUTICALS, INC.Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
-
Publication number: 20140271640Abstract: The present disclosure provides complexes comprising an FGF-10 portion and a heterologous protein or peptide, as well as methods of using such complexes.Type: ApplicationFiled: December 6, 2013Publication date: September 18, 2014Applicant: PERMEON BIOLOGICS, INC.Inventors: Katherine S. Bowdish, Erik M. Vogan, John F. Ross, Ann Dewitt
-
Publication number: 20140271622Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using copper, are described.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: MOMENTA PHARMACEUTICALS, INC.Inventor: Holly Prentice
-
Publication number: 20140274761Abstract: The invention relates to an isolated nucleic acid sequence comprising a promoter, which is a native sequence of Pichia pastoris comprising the nucleic acid sequence of pCS1 of SEQ ID NO:1, or a functionally active variant thereof which is a size variant, a mutant or hybrid of SEQ ID NO:1, or a combination thereof, expression constructs and recombinant host cells comprising the promoter, and a method of producing a protein of interest under the control of the promoter. It further relates to a method to identify a constitutive promoter from eukaryotic cells, and an isolated nucleic acid sequence comprising a promoter which when operatively linked to a nucleotide sequence encoding a protein of interest directs the expression thereof in a host cell at an expression level that is higher than under control of the native pGAP promoter at high and low growth rates.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: LONZA LTDInventors: Diethard Mattanovich, Brigitte Gasser, Roland Prielhofer
-
Patent number: 8834866Abstract: The present invention provides chimeric polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need.Type: GrantFiled: June 15, 2010Date of Patent: September 16, 2014Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Publication number: 20140255401Abstract: The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Applicant: Janssen Biotech, Inc.Inventors: Ellen Chi, Wilson Edwards, Chichi Huang, Wai-Ping Leung, Ronald Swanson, Alan Wickenden
-
Publication number: 20140255993Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures by changing the temperature of the cell culture and/or by starving the cells in their asparagine supply.Type: ApplicationFiled: June 29, 2012Publication date: September 11, 2014Applicant: AMGEN INC.Inventors: Brian D. Follstad, Rebecca E. McCoy, Arvia E. Morris
-
Publication number: 20140255361Abstract: Disclosed herein are systems, methods and compositions for rapidly and reversibly destabilizing a target protein in vitro or in vivo, in the presence or absence of a cell-permeable, synthetic molecule or ligand.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: The Board of Trustees Of The Leland Stanford Junior UniversityInventors: Thomas J. Wandless, Ling-chun Chen
-
Patent number: 8829161Abstract: Various embodiments are directed to transgenic plants, including transgenic tobacco plants and derivative seeds, genetically modified to impede the transport of Cadmium (Cd) from the root system to aerial portions of transgenic plants by reducing the expression levels of HMA-related transporters. Various embodiments are directed to transgenic tobacco plants genetically modified to stably express a RNAi construct encoding RNAi polynucleotides that enable the degradation of endogenous NtHMA RNA variants. Reduced expression of NtHMA transporters in transgenic plants results in substantially reduced content of Cadmium (Cd) in the leaf lamina. Various consumable products that are substantially free or substantially reduced in Cd content can be produced by incorporating leaves derived from transgenic tobacco plants modified to reduce the expression of NtHMA transporters.Type: GrantFiled: February 19, 2013Date of Patent: September 9, 2014Assignee: Philip Morris USA Inc.Inventors: Alec J. Hayes, Chengalrayan Kudithipudi, Rutger S. van der Hoeven
-
Patent number: 8828690Abstract: Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding multizymes (i.e., single polypeptides having at least two independent and separable enzymatic activities) along with a method of making long-chain polyunsaturated fatty acids (PUFAs) using these multizymes in plants and oleaginous yeast are disclosed.Type: GrantFiled: April 3, 2008Date of Patent: September 9, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Howard G. Damude, Anthony J. Kinney, Kevin G. Ripp, Quinn Qun Zhu
-
Patent number: 8828676Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.Type: GrantFiled: October 26, 2011Date of Patent: September 9, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
-
Patent number: 8828686Abstract: The invention relates to mammalian PAI-I ligands and modulators. In particular, the invention relates to polypeptides, polypeptide compositions and polynucleotides that encode polypeptides that are ligands and/or modulators of PAI-I. The invention also relates to polyligands that are homopolyligands or heteropolyligands that modulate PAI-I activity. The invention also relates to ligands and polyligands localized to a region of a cell. The invention also relates to localization tethers and promoter sequences that can be used to provide spatial control of the PAI-I ligands and polyligands. The invention also relates to inducible gene switches that can be used to provide temporal control of the PAI-I ligands and polyligands. The invention also relates to methods of treating or preventing atherosclerosis. The invention also relates to methods of treating or preventing fibrosis.Type: GrantFiled: February 15, 2013Date of Patent: September 9, 2014Assignee: Intrexon CorporationInventors: Thomas D. Reed, Richard E. Peterson, Charles E. Reed, Joan Mazzarelli Sopczynski, Bethany L. Merenick, Jonathan Carson, Catherine L. Keaty, Elena Tasheva
-
Patent number: 8828700Abstract: Fusion proteins comprising a single strand DNA binding protein and a nucleic acid polymerase (e.g. DNA polymerase or reverse transcriptase). These high fidelity proteins are suitable for use in nucleic acid amplification methods, including the polymerase chain reaction (PCR).Type: GrantFiled: December 1, 2008Date of Patent: September 9, 2014Assignee: Life Technologies CorporationInventors: Jun Lee, Robert Potter, David Mandelman
-
Publication number: 20140249295Abstract: Disclosed herein are a light-inducible system and method for rapidly and reversibly modulating protein stability and function. This system and method employs conditionally stable protein domains that regulate the degradation of a fusion protein depending upon the presence or absence of a particular light source.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: The Board of Trustees Of The Leland Stanford Junior UniversityInventors: Kimberly M. Bonger, Rishi Rakhit, Thomas J. Wandless
-
Patent number: 8822181Abstract: A method for forming a fusion protein that is expressed as a recombinant protein body-like assembly in host eukaryotic cells and organisms other than higher plants as host systems is disclosed. More particularly, peptides and proteins are fused to protein sequences that mediate the induction of recombinant protein body-like assembly (RPBLA) formation, are stably expressed and accumulated in these host cells after transformation with an appropriate vector. Methods for preparing the fusion protein are also disclosed.Type: GrantFiled: November 29, 2005Date of Patent: September 2, 2014Assignee: ERA Biotech S.A.Inventors: Margarita Torrent, Miriam Bastida, Pablo Marzábal, Blanca Llompart, Ma Dolores Ludevid
-
Patent number: 8821892Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: January 8, 2013Date of Patent: September 2, 2014Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King